https://centerforbiosimilars.com

Center for Biosimilars®biosimilars,biosimilar,interchangeability,interchangeable biosimilars,interchangeable biosimilar,biosimilar resources,bio-betters,biobetters,biologics,biologic drugs,biosimilar savings,biosimilar development,biosimilars in the clinical setting,biologic medications,biosimilar drugs,biosimilar medications,oncology biosimilars,rheumatology biosimilars,ophthalmology biosimilars,biosimilar insulin,biosimilar insulinsCenter for Biosimilars® NewsAll NewsProduct Approvals and LaunchesMediaAll VideosInsightsInterviewsPeer ExchangePodcastsStakeholder SummitCompendiaBone HealthDermatologyDiabetesGastroenterologyHematologyImmunologyNeurologyOncologyOphthalmologyRare DiseaseRespiratoryRheumatologyConferencesConference CoverageConference ListingCME/CEResourcesAuthorsBiosimilar ResourcesInteractive ToolsPartnersPolls and QuizzesSponsoredWHEN CHOICE ARRIVES: Competition & ConsequencesSubscribeBIOSIMILAR APPROVALS Business PracticeBusinessDevelopmentLegalPolicyPracticeRegulatoryNewsAll NewsProduct Approvals and LaunchesMediaAll VideosInsightsInterviewsPeer ExchangePodcastsStakeholder SummitCompendiaBone HealthDermatologyDiabetesGastroenterologyHematologyImmunologyNeurologyOncologyOphthalmologyRare DiseaseRespiratoryRheumatologyConferencesConference CoverageConference ListingCME/CEResourcesAuthorsBiosimilar ResourcesInteractive ToolsPartnersPolls and QuizzesSponsoredWHEN CHOICE ARRIVES: Competition & ConsequencesSubscribeBIOSIMILAR APPROVALSChoose a SpecialtyBone HealthImmunologyHematologyRespiratoryDermatologyDiabetesGastroenterologyNeurologyOncologyOphthalmologyRare DiseaseRheumatologyAdvertisementBusiness PracticeBusinessDevelopmentLegalPolicyPracticeRegulatoryLatest News Bevacizumab Biosimilars Show Similar Efficacy, Safety in NSCLCBy Cameron SantoroFebruary 27th 2025Adalimumab Biosimilar Switching Policy Shows Long-Term Success in IBD By Skylar JeremiasFebruary 26th 2025Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory RequirementsBy Cameron SantoroFebruary 25th 20253 Ustekinumab Biosimilars Launch on US MarketBy Skylar JeremiasFebruary 25th 2025Will the FTC Be More PBM-Friendly Under a Second Trump Administration?By Skylar JeremiasFebruary 23rd 2025Latest VideosRegister for IGBA's Global Biosimilars Week LIVE Webinar!Visit NowContinuing Medical EducationPodcastOn-DemandChallenges in Treatment of Desmoid Tumors and Managed Care Solutions0.5 Credit / OncologyView MoreOnline ArticleOn-DemandDesmoid Tumors: What Managed Care Professionals Need to Know to Manage These Unpredictable Tumors, featuring a...2.0 Credits / OncologyView MoreAJMC SupplementOn-DemandNavigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care2.0 Credits / Ophthalmology/OptometryView MoreOn-Demand Virtual SymposiumOn-DemandAddressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Manage...1.5 Credits / Hematology, Hematologic Cancer, OncologyView MoreOn-Demand Virtual SymposiumOn-DemandNovel Therapies and Emerging Strategies for HR+/HER2- Metastatic Breast Cancer and the Impact on Patient Outco...1.5 Credits / Oncology, Breast CancerView MoreOn-Demand Virtual SymposiumOn-DemandApplication of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed...1.5 Credits / Ophthalmology, OptometryView MoreOn-Demand Virtual SymposiumOn-DemandEmerging Concepts and Approaches in the Treatment of Food Allergy: What Managed Care Professionals Need to Kno...1.5 Credits / Immunology, AllergyView MoreOn-Demand Virtual SymposiumOn-DemandKeeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodi...1.5 Credits / Oncology, Hematology, Hematologic CancerView MoreAll NewsResolution of Injection Site Reactions After Switching to Adalimumab BiosimilarBy Deana Ferreri, PhDFebruary 22nd 2025A 15-year-old girl with ulcerative colitis who developed injection site reactions to the adalimumab reference product was successfully switched to the biosimilar LBAL without recurrence of symptoms, demonstrating the safety and effectiveness of switching for medical reasons, likely due to an allergic reaction to an excipient in the originator.EC Approves Celltrion Denosumab, Aflibercept BiosimilarsBy Skylar JeremiasFebruary 20th 2025Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar (Eydenzelt).FDA, EMA Approve Second Pair of Denosumab BiosimilarsBy Skylar JeremiasFebruary 17th 2025The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' denosumab biosimilars, which will be marketed under different names depending on whether they will be used to treat osteoporosis or bone metastases.Teriparatide Biosimilar Shows Comparable Efficacy to Reference Drug in Postmenopausal OsteoporosisBy Cameron SantoroFebruary 17th 2025Researchers treated postmenopausal women with osteoporosis with teriparatide biosimilar RGB-10, which improved their bone health measures and reduced fracture risk comparably to reference teriparatide.FDA Approves First Insulin Aspart BiosimilarBy Skylar JeremiasFebruary 17th 2025The FDA approved Merilog (insulin-aspart-szjj) as the first biosimilar to reference Novolog (insulin aspart) for the treatment of adult and pediatric patients with type 2 diabetes.BioRationality: A Socratic Analysis of IQVIA Report on BiosimilarsBy Sarfaraz K. Niazi, PhDFebruary 17th 2025Sarfaraz K. Niazi, PhD, gives his opinion on how the recent IQVIA report “Assessing the Biosimilar Void in the US” could be improved for the future.Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD By Deana Ferreri, PhDFebruary 15th 2025Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study. Biosimilars Fuel Price Cuts in European Insulin Glargine MarketsBy Skylar JeremiasFebruary 14th 2025Although Lantus continues to lead the insulin glargine market globally, the rise of biosimilars like Abasaglar and Semglee has sparked significant price reductions, with some European countries seeing discounts of up to 42.3%.Robert F. Kennedy Jr Confirmed as HHS Secretary, Nearly Along Party LinesBy Christina MattinaFebruary 13th 2025The Senate voted 52-48 to confirm Robert F. Kennedy Jr as secretary of HHS, setting up the vaccine skeptic to carry out major changes in pursuit of his Make America Healthy Again agenda.Psoriasis Biosimilars Saved VA $67 Million in 2023By Skylar JeremiasFebruary 12th 2025The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high costs of biologic therapies to treat chronic disease.The Future of Pharmacy: Trends, Threats, TransformationsBy Cameron SantoroFebruary 11th 2025The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation.Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market PotentialBy Dracey PooreFebruary 10th 20252025 marks a pivotal year for biosimilars with Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey Poore, MS, of Cardinal Health.Biosimilars in Action: Market Shifts, Legal Insights, and FDA ApprovalsBy Skylar JeremiasFebruary 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal CancerBy Deana Ferreri, PhDFebruary 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care MarketsBy Skylar JeremiasFebruary 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.Interchangeable Aflibercept Biosimilar, Enzeevu, Comparable With Eylea for nAMDBy Cameron SantoroFebruary 6th 2025Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in patients with neovascular age-related macular degeneration (nAMD).The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack BiosimilarsBy Skylar JeremiasFebruary 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.The Banking of Biosimilars: Insights From a Leading Health EconomistBy Skylar Jeremias James D. Chambers, PhD, MPharm, MScFebruary 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.BioRationality: No More Biosimilars—Just BiogenericsBy Sarfaraz K. Niazi, PhDFebruary 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.Biosimilars Rheumatology Roundup: January 2025By Skylar JeremiasFebruary 1st 2025January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, and the FDA approval of the third tocilizumab biosimilar.Welcome Wezlana: The First Stelara Biosimilar to Launch in the USBy Skylar JeremiasJanuary 31st 2025January 1 marks the launch of the first biosimilar referencing Stelara (ustekinumab) in the US, ushering in a new class of lower-cost medicines for patients with rheumatic and gastrointestinal conditions.FDA Approves Celltrion's Avtozma as Third Tocilizumab BiosimilarBy Skylar JeremiasJanuary 31st 2025The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions. It is the third biosimilar to reference Actemra (tocilizumab) to be approved for US patients.Real-World UK, Ireland Study Confirms Long-Term Efficacy of SB5 in PsoriasisBy Skylar JeremiasJanuary 30th 2025SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.FDA Reviews Golimumab Biosimilar, Samsung Biologics Hits Record Sales, Japan Approves Stelara BiosimilarBy Cameron SantoroJanuary 30th 2025The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese regulatory agency approved a Stelara biosimilar.Integrating Biosimilars Into Retina and Neurology Practices Requires Careful PlanningBy Derek Burns, PharmD, MBA, BCPS, BCSCPLisa Lasita, PharmD, MBA January 29th 2025Successfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.See All News >AboutEditorialContactAdvisory BoardDo Not Sell My InformationTerms & ConditionsPrivacy PolicyContact Info2 Commerce Drive Cranbury, NJ 08512609-716-7777© 2025 MJH Life Sciences All rights reserved.enenhttps://centerforbiosimilars.com

Saytingizni tahrirlaysizmi?

Nima qilyapsiz?